Krystal Biotech, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 |
| Selling, general & administrative | $146.7M | $113.6M | $98.3M | $77.7M | — |
| Research and development | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M |
| Operating expenses | $227.8M | $224.8M | $160.3M | $145.2M | $68.3M |
| Operating income | $161.3M | $65.7M | -$109.6M | -$145.2M | -$68.3M |
| Interest expense | — | — | $0 | $0 | $1.5M |
| Pretax income | $189.5M | $95.4M | $12.9M | -$140.0M | -$69.6M |
| Income tax expense | -$15.4M | $6.2M | $2.0M | $0 | $0 |
| Net income | $204.8M | $89.2M | $10.9M | -$140.0M | -$69.6M |
| Balance Sheet | |||||
| Cash and equivalents | $496.3M | $344.9M | $358.3M | $161.9M | $341.2M |
| Current assets | $1.0B | $742.0M | $587.9M | $383.8M | $442.3M |
| Total assets | $1.3B | $1.1B | $818.4M | $558.5M | $626.3M |
| Current liabilities | $102.9M | $102.0M | $33.1M | $28.8M | $25.7M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M |
| Stockholders' equity | $1.2B | $946.4M | $778.6M | $522.2M | $593.6M |
| Cash Flow Statement | |||||
| Cash from operations | $200.9M | $123.4M | -$88.8M | -$100.6M | -$47.9M |
| Depreciation and amortization | $5.7M | $6.0M | $5.0M | $4.1M | $2.8M |
| Stock-based compensation | $54.5M | $49.1M | $39.9M | $33.2M | $15.3M |
| Capital expenditure | $12.0M | $4.2M | $11.8M | $53.0M | $68.3M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M | -$116.3M |
| Impairments | — | — | $0 | $0 | $0 |
Shares outstanding 29.5M · Free float 65.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.